Stimulation Test With Intranasal Glucagon for Corticotroph, Somatotroph &

Status Completed

Clinical Trial Summary

The diagnosis of secondary hypoadrenalism and GH deficiency (GHD) often requires the performance of a dynamic test. The glucagon stimulation test (GST) is one of the options for evaluating hypothalamic-pituitary function, representing a stimulus for both the corticotropic and somatotropic axis, substantially safe and easily available. The standard procedure involves the intramuscular injection of 1-1.5 mg of glucagon based on the patient's weight. In addition to its antero-pituitary function, glucagon has also shown its ability to stimulate neurohypophyseal secretion. Using the copeptin dosage, it has been shown that after the administration of glucagon in healthy subjects there is a significant release of ADH. However, the available data are scarse and there is no standardized protocol for the use of the glucagon test in diabetes insipidus. At the moment, GST is not the most frequently chosen diagnostic option. In fact, despite having the advantage of being able to investigate different areas of anterohypophyseal and probably posterohypophyseal function at the same time, the test has some disadvantages: the prolonged duration makes the procedure challenging, the intramuscular injection can be unwelcome, and many variables can come into play in the definition of a normal response (age, BMI, glycemic status). The recent introduction of a single-dose nasal powder formulation (Baqsimi®) could overcome some of the limitations of classic GST and make the procedure less demanding. To date, no assessments are yet available regarding a purely diagnostic role in the context of hypopituitarism of this new formulation. Through the knowledge of the physiological response of the adrenocortical, somatotropic and ADH axis to the administration of intranasal glucagon in healthy subjects, it will be possible to evaluate its possible application in the diagnosis of GH deficiency, central adrenal insufficiency and possibly diabetes insipidus.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Hypopituitarism

Clinical Trial Details

NCT number	NCT05206149
Study type	Interventional
Source	Azienda Ospedaliera Città della Salute e della Scienza di Torino
Contact
Status	Completed
Phase	Phase 4
Start date	October 1, 2021
Completion date	December 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT02871986` - Pubertal Induction in Individuals With Hypogonadism	N/A
Completed	`NCT00851942` - Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test	Phase 4
Completed	`NCT00507104` - Pituitary Functions After Traumatic Brain Injury (TBI) and/or Subarachnoid Hemorrhage (SAH)
Completed	`NCT01088399` - A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults	N/A
Completed	`NCT00027430` - Androgen Replacement Therapy in Women With Hypopituitarism	N/A
Recruiting	`NCT04897802` - Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)	Phase 4
Not yet recruiting	`NCT06014398` - Improving Survivorship and Health-related Quality of Life in Patients With Primary Brain Tumours	N/A
Recruiting	`NCT04121780` - Growth Hormone Replacement Therapy for Retried Professional Football Players	Phase 2
Not yet recruiting	`NCT01666964` - Hormone Deficiency After Brain Injury During Combat	N/A
Completed	`NCT01028742` - Posttraumatic Hypopituitarism - Incidence, Predictors and Test Validity	N/A
Completed	`NCT00139945` - Ghrelin, Growth Hormone and Cortisol Interaction in Growth Hormone Deficient Patients	N/A
Completed	`NCT05188131` - Acute Neuroendocrine Response to Intravenous Infusion of Diclofenac Sodium	Phase 4
Completed	`NCT00133354` - Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys	Phase 2/Phase 3
Not yet recruiting	`NCT03708523` - Next Day Growth Hormone Predicting Pituitary Function After Adenomectomy
Completed	`NCT01007071` - Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency	Phase 3
Not yet recruiting	`NCT06326853` - Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models
Completed	`NCT00080483` - Testosterone and Growth Hormone for Bone Loss in Men	Phase 2
Completed	`NCT01009905` - An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)	N/A
Completed	`NCT01209416` - The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin	N/A
Completed	`NCT04902235` - Identification and Clinical Relevance of an Oxytocin Deficient State (CRH Study)	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Stimulation Test With Intranasal Glucagon for Corticotroph, Somatotroph and Antidiuretic Axes

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms